- Home
- JKHY vs EXEL Comparison
JKHY vs EXEL Comparison
Compare JKHY & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKHY
- EXEL
- Stock Information
- Founded
- JKHY 1976
- EXEL 1994
- Country
- JKHY United States
- EXEL United States
- Employees
- JKHY N/A
- EXEL N/A
- Industry
- JKHY Retail: Computer Software & Peripheral Equipment
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JKHY Technology
- EXEL Health Care
- Exchange
- JKHY Nasdaq
- EXEL Nasdaq
- Market Cap
- JKHY 12.6B
- EXEL 10.4B
- IPO Year
- JKHY N/A
- EXEL 2000
- Fundamental
- Price
- JKHY $152.38
- EXEL $38.85
- Analyst Decision
- JKHY Hold
- EXEL Buy
- Analyst Count
- JKHY 9
- EXEL 22
- Target Price
- JKHY $178.00
- EXEL $44.00
- AVG Volume (30 Days)
- JKHY 1.3M
- EXEL 2.4M
- Earning Date
- JKHY 11-04-2025
- EXEL 10-28-2025
- Dividend Yield
- JKHY 1.52%
- EXEL N/A
- EPS Growth
- JKHY 19.31
- EXEL 81.76
- EPS
- JKHY 6.24
- EXEL 2.08
- Revenue
- JKHY $2,375,288,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- JKHY $6.98
- EXEL $9.10
- Revenue Next Year
- JKHY $6.41
- EXEL $12.47
- P/E Ratio
- JKHY $24.51
- EXEL $18.88
- Revenue Growth
- JKHY 7.21
- EXEL 10.73
- 52 Week Low
- JKHY $144.12
- EXEL $27.86
- 52 Week High
- JKHY $196.00
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- JKHY 47.76
- EXEL 46.69
- Support Level
- JKHY $147.98
- EXEL $37.52
- Resistance Level
- JKHY $155.96
- EXEL $40.53
- Average True Range (ATR)
- JKHY 2.65
- EXEL 1.06
- MACD
- JKHY 1.08
- EXEL -0.10
- Stochastic Oscillator
- JKHY 69.74
- EXEL 31.44
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.